Comparative Pharmacology
Head-to-head clinical analysis: DECLOMYCIN versus RETET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECLOMYCIN versus RETET.
DECLOMYCIN vs RETET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting aminoacyl-tRNA binding to the mRNA-ribosome complex, thereby blocking protein synthesis.
RETET is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors, thereby blocking estrogen-mediated signaling in target tissues.
150 mg orally every 6 hours or 300 mg orally every 12 hours.
No standard dosing available; RETET is not a recognized therapeutic agent. Please verify drug name.
None Documented
None Documented
Terminal elimination half-life 10-17 hours; prolonged to 18-48 hours in renal impairment
Terminal elimination half-life 18-24 hours in healthy adults; prolonged to 30-40 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal: ~50% unchanged; biliary/fecal: ~40% as inactive metabolites; enterohepatic recycling occurs
Renal: 70-80% unchanged; Fecal: 10-15%; Biliary: <5%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic